Search

Your search keyword '"Leung, Sharon Shui Yee"' showing total 45 results
Start Over Author "Leung, Sharon Shui Yee"
45 results on '"Leung, Sharon Shui Yee"'

25. Virus-Mimicking Mesoporous Silica Nanoparticles with an Electrically Neutral and Hydrophilic Surface to Improve the Oral Absorption of Insulin by Breaking Through Dual Barriers of the Mucus Layer and the Intestinal Epithelium

Author

Zhang, Yi, primary, Xiong, Mengting, additional, Ni, Xiaomin, additional, Wang, Jingrou, additional, Rong, Hehui, additional, Su, Yuqing, additional, Yu, Shihui, additional, Mohammad, Imran Shair, additional, Leung, Sharon Shui Yee, additional, and Hu, Haiyan, additional

Published
2021
Full Text
View/download PDF

27. Bacteriophage endolysins against gram-positive bacteria, an overview on the clinical development and recent advances on the delivery and formulation strategies.

Author

Ho, Marco Kai Yuen, Zhang, Pengfei, Chen, Xi, Xia, Jiang, and Leung, Sharon Shui Yee

Subjects
BACTERIOPHAGES, GRAM-positive bacteria, LYSINS, DRUG resistance in bacteria, MULTIDRUG resistance
Abstract

Facing the increasing threat of multi-drug antimicrobial resistance (AMR), humans strive to search for antibiotic drug candidates and antibacterial alternatives from all possible places, from soils in remote areas to deep in the sea. In this "gold rush for antibacterials," researchers turn to the natural enemy of bacterial cells, bacteriophage (phages), and find them a rich source of weapons for AMR bacteria. Endolysins (lysins), the enzymes phages use to break the bacterial cells from within, have been shown to be highly selective and efficient in killing their target bacteria from outside while maintaining a low occurrence of bacterial resistance. In this review, we start with the structures and mechanisms of action of lysins against Gram-positive (GM+) bacteria. The developmental history of lysins is also outlined. Then, we detail the latest preclinical and clinical research on their safety and efficacy against GM+ bacteria, focusing on the formulation strategies of these enzymes. Finally, the challenges and potential hurdles are discussed. Notwithstanding these limitations, the trends in development indicate that the first, approved lysin drugs will be available soon in the near future. Overall, this review presents a timely summary of the current progress on lysins as antibacterial enzymes for AMR GM+ bacteria, and provides a guidebook for biomaterial researchers who are dedicating themselves to the battle against bacterial infections. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

31. Potential of Inhaled Bacteriophage Therapy for Bacterial Lung Infection

Author

Leung, Sharon Shui Yee, To, Kenneth K.W., Mukhopadhyay, Subhankar, and Yan, Wei

Subjects
Medical
Abstract

Phage therapy as a promising alternative antimicrobial to treat multidrug resistant (MDR) bacteria related lung infections, has drawn significant attention in clinical trials and bench-scale study in the recent decade, and the therapeutic effect of local delivery of phage has been demonstrated by several clinical reports. This book chapter discusses the current clinical development of inhaled phage therapy followed by the advancement of phage formulation designs for respiratory delivery of phage using various inhalation devices and their in vivo efficacy. The development of combination therapy of phage and antibiotics to combat MDR bacteria associated lung infections is also covered to reflect the current clinical practice. Lastly, we also share our insights on the challenges of advancing inhaled phage therapy and potential directions for future research.

Published
2019

37. Nebulisation effects on structural stability of bacteriophage PEV44

Author

Astudillo, Ariel, Leung, Sharon Shui Yee, Kutter, Elizabeth, Morales, Sandra, Britton, Warwick J, and Chan, Hak-Kim

Subjects
110203 - Respiratory Diseases [FoR], viruses, phage, nebulizer, PEV44, 111504 - Pharmaceutical Sciences [FoR]
Abstract

Nebulization being used for inhaled phage therapy can cause phage titer losses which may be the result of mechanical damage to the phages. This study aimed to determine effects of nebulization on the structural stability and bioactivity of a Pseudomonas lytic phage PEV44, which is a myovirus consisting of a hexagonal head and a contractile tail connected by a neck. Australian Research Council

Published
2017

45. A Proof-of-Principle Setup for Delivery of Relenza ® (Zanamivir) Inhalation Powder to Intubated Patients.

Author

Leung SSY, Parumasivam T, Tang P, and Chan HK

Abstract

Background: A fatal incident was reported when a mechanical ventilated patient received nebulization of a reconstituted Relenza ® formulation. We propose a delivery system to introduce Relenza and other inhalation dry powders to intubated patients to avoid accidental fatalities in the future., Methods: This is a bench study demonstrating the feasibility of a delivery system to introduce dry powder of Relenza to intubated patients. A dry powder inhaler placed within a delivery chamber was actuated by compressing a ventilation bag to disperse powder into a tracheal tube. The performance of two inhalers, a Diskhaler ® and an Osmohaler ™ , were compared. The effects of the length and size of the tracheal tube on the powder output and sizing of emitted powder were investigated using the more efficient Osmohaler ™ ., Results: The efficiency of Osmohaler in delivering Relenza to the distal end [delivered dose=30.2±0.2% and fine particle fraction (FPF)=14.5±1.7%] was significantly higher than the Diskhaler (delivered dose=18.1±4.7% and FPF=3.4±2.1%). While no differences in the delivered dose and FPF were observed between the tracheostomy and endotracheal tubes of the same internal diameter, a larger endotracheal tube (9.0 mm internal diameter) gave a 6% higher FPF compared with the smaller counterpart (7.0 mm internal diameter)., Conclusion: The dry powder delivery system has been demonstrated to be capable of delivering Relenza formulation to the distal end of tracheal tubes with a reasonable delivered dose and FPF. It would be necessary for further investigation into incorporating the proposed powder delivery system within a mechanical ventilator, as well as animal and clinical studies to prove its applicability to deliver zanamivir dry powder to ventilated influenza patients in the intensive care setting.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results